Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Sun, Aiqin ^a   Yu, Guanzhen ^b   Dou, Xiaoyan ^a   Yan, Xiaowei ^c   Yang, Wannian ^d   Lin, Qiong ^a,d  

^a JIANGSU UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Center for Health Research   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

Author keywords

Gastric cardia adenocarcinoma; Nedd4 1; Prognostic biomarker; Survival prediction

Indexed keywords

UBIQUITIN PROTEIN LIGASE NEDD4; ESCRT PROTEIN; NEDD4 UBIQUITIN PROTEIN LIGASES; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE;

ADULT; ARTICLE; CANCER CELL LINE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARDIA CARCINOMA; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH SURGERY; TISSUE MICROARRAY; ADENOCARCINOMA; CELL LINE; CELL MOTION; GENETICS; HEK293 CELL LINE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; FEMALE; HEK293 CELLS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 84934892901     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-248     Document Type: Article

References (44)

1. Ohno S, Tomisaki S, Oiwa H, Sakaguchi Y, Ichiyoshi Y, Maehara Y, Sugimachi K: Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. J Am Coll Surg 1995,180(5):577-582.
2. Rüdiger Siewert J, Feith M, Werner M, Stein HJ: Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000,232(3):353-361. 10.1097/00000658-200009000-00007
3. Nakane Y, Okamura S, Boku T, Okusa T, Tanaka K, Hioki K: Prognostic differences of adenocarcinoma arising from the cardia and the upper third of the stomach. Am Surg 1993,59(7):423-429.
4. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 1, 345:725-729. 10.1056/NEJMoa010187
5. Feng AN, Zhang LH, Fan XS, Huang Q, Ye Q, Wu HY, Yang J: Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. Int J Surg Pathol 2011,19(6):743-750. 10.1177/1066896911412181
6. Pinto-de-Sousa J, David L, Almeida R, Leitão D, Preto JR, Seixas M, Pimenta A: c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002,10(4):247-256. 10.1177/106689690201000402
7. Liu M, Li JS, Tian DP, Huang B, Rosqvist S, Su M: MCM2 expression levels predict diagnosis and prognosis in gastric cardiac cancer. Histol Histopathol 2013,28(4):481-492.
8. Shi R, Wang L, Wang T, Xu J, Wang F, Xu M: NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma. Med Oncol 2014,31(3):852.
9. Zhang Q, Wang H, Ma Y, Zhang J, He X, Ma J, Zhao ZS: Overexpression of Nedd9 is a prognostic marker of human gastric cancer. Med Oncol 2014,31(7):33.
10. Liu Y, Wang D, Zhao KL, Zhu JW, Yin HB, Wei YZ, Wu ZJ, Cheng GJ, Wang F, Ni F, Wang XL, Cao GX, Huang J, Cai J: NEDD9 overexpression correlates with poor prognosis in gastric cancer. Tumour Biol 2014,35(7):6351-6356. 10.1007/s13277-014-1839-7
11. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006,24(30):4922-4927. 10.1200/JCO.2006.07.1316
12. Staub O, Gautschi I, Ishikawa T, Breitschopf K, Ciechanover A, Schild L, Rotin D: Regulation of stability and function of the epithelial Na + channel (ENaC) by ubiquitination. EMBO J 1997,16(21):6325-6336. 10.1093/emboj/16.21.6325
13. Staub O, Dho S, Henry P, Correa J, Ishikawa T, McGlade J, Rotin D: WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na + channel deleted in Liddle's syndrome. EMBO J 1996,15(10):2371-2380.
14. Persaud A, Alberts P, Amsen EM, Xiong X, Wasmuth J, Saadon Z, Fladd C, Parkinson J, Rotin D: Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays. Mol Syst Biol 2009, 5:333-350.
15. Magnifico A, Ettenberg S, Yang C, Mariano J, Tiwari S, Fang S, Lipkowitz S, Weissman AM: WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation. J Biol Chem 1, 278:43169-43177. 10.1074/jbc.M308009200
16. Woelk T, Oldrini B, Maspero E, Confalonieri S, Cavallaro E, Di Fiore PP, Polo S: Molecular mechanisms of coupled monoubiquitination. Nat Cell Biol 1, 8:1246-12454. 10.1038/ncb1484
17. Blot V, Perugi F, Gay B, Prévost MC, Briant L, Tangy F, Abriel H, Staub O, Dokhélar MC, Pique C: Nedd4.1-mediated ubiquitination and subsequent recruitment of Tsg101 ensure HTLV-1 Gag trafficking towards the multivesicular body pathway prior to virus budding. J Cell Sci 2004,117(Pt 11):2357-2367.
18. Katz M, Shtiegman K, Tal-Or P, Yakir L, Mosesson Y, Harari D, Machluf Y, Asao H, Jovin T, Sugamura K, Yarden Y: Ligand-independent degradation of epidermal growth factor receptor involves receptor ubiquitylation and Hgs, an adaptor whose ubiquitin-interacting motif targets ubiquitylation by Nedd4. Traffic 2002,3(10):740-751. 10.1034/j.1600-0854.2002.31006.x
19. Aoh QL, Castle AM, Hubbard CH, Katsumata O, Castle JD: SCAMP3 negatively regulates epidermal growth factor receptor degradation and promotes receptor recycling. Mol Biol Cell 2009,20(6):1816-1832. 10.1091/mbc.E08-09-0894
20. Lin Q, Wang J, Childress C, Sudol M, Carey DJ, Yang W: HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates EGF-induced degradation of EGFR and ACK. Mol Cell Biol 1, 30:1541-1554. 10.1128/MCB.00013-10
21. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, Jiang X: NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 1, 128:129-139. 10.1016/j.cell.2006.11.039
22. Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, Franco R, Botti G, Pirozzi P, Rocco G, De Rosa N, Viglietto G: Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol 2010,177(5):2622-2634. 10.2353/ajpath.2010.091075
23. Hong SW, Moon JH, Kim JS, Shin JS, Jung KA, Lee WK, Jeong SY, Hwang JJ, Lee SJ, Suh YA, Kim I, Nam KY, Han S, Kim JE, Kim KP, Hong YS, Lee JL, Lee WJ, Choi EK, Lee JS, Jin DH, Kim TW: p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN. Cell Death Differ 2014,21(1):146-160. 10.1038/cdd.2013.141
24. Jung S, Li C, Jeong D, Lee S, Ohk J, Park M, Han S, Duan J, Kim C, Yang Y, Kim KI, Lim JS, Kang YS, Lee MS: Oncogenic function of p34SEI-1 via NEDD4-1-mediated PTEN ubiquitination/degradation and activation of the PI3K/AKT pathway. Int J Oncol 2013,43(5):1587-1595.
25. Yang Z, Yuan XG, Chen J, Lu NH: Is NEDD4-1 a negative regulator of phosphatase and tensin homolog in gastric carcinogenesis? World J Gastroenterol 2012,18(43):6345-6348. 10.3748/wjg.v18.i43.6345
26. Kim SS, Yoo NJ, Jeong EG, Kim MS, Lee SH: Expression of NEDD4-1, a PTEN regulator, in gastric and colorectal carcinomas. APMIS 2008,116(9):779-784. 10.1111/j.1600-0463.2008.00999.x
27. Fouladkou F, Landry T, Kawabe H, Neeb A, Lu C, Brose N, Stambolic V, Rotin D: The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci U S A 2008,105(25):8585-8590. 10.1073/pnas.0803233105
28. Maddika S, Kavela S, Rani N, Palicharla VR, Pokorny JL, Sarkaria JN, Chen J: WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol 2011,13(6):728-733.
29. Eide PW, Cekaite L, Danielsen SA, Eilertsen IA, Kjenseth A, Fykerud TA, Ågesen TH, Bruun J, Rivedal E, Lothe RA, Leithe E: NEDD4 is overexpressed in colorectal cancer and promotes colonic cell growth independently of the PI3K/PTEN/AKT pathway. Cell Signal 2013,25(1):12-18. 10.1016/j.cellsig.2012.08.012
30. Salah Z, Cohen S, Itzhaki E, Aqeilan RI: NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation. Cell Cycle 2013,12(24):3817-3823. 10.4161/cc.26672
31. Park JG, Frucht H, LaRocca RV, Bliss DP Jr, Kurita Y, Chen TR, Henslee JG, Trepel JB, Jensen RT, Johnson BE, Bang Y-J, Kim J-P, Gazdar AF: Characteristics of cell lines established from human gastric carcinoma. Cancer Res 1990, 50:2773-2780.
32. Barranco SC, Townsend CM Jr, Casartelli C, Macik BG, Burger NL, Boerwinkle WR, Gourley WK: Establishment and characterization of an in vitro model system for human adenocarcinoma of the stomach. Cancer Res 1983,43(4):1703-1709.
33. Lin HL, Chiou SH, Wu CW, Lin WB, Chen LH, Yang YP, Tsai ML, Uen YH, Liou JP, Chi CW: Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells. J Pharmacol Exp Ther 2007,323(1):365-373. 10.1124/jpet.107.124966
34. Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, Yu K, Rha SY, Chung HC, Ylstra B, Meijer G, Lian KO, Grabsch H, Tan P: Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res 2008,68(11):4277-4286. 10.1158/0008-5472.CAN-07-6517
35. Shen Z, Kauttu T, Seppänen H, Vainionpää S, Ye Y, Wang S, Mustonen H, Puolakkainen P: Both macrophages and hypoxia play critical role in regulating invasion of gastric cancer in vitro. Acta Oncol 2013,52(4):852-860. 10.3109/0284186X.2012.718444
36. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, Kim HJ, Misteli T, Jiang X, Pandolfi PP: Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007,128(1):141-156. 10.1016/j.cell.2006.11.040
37. Arteaga C: Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003,30(3 Suppl 7):3-14.
38. Tysnes BB, Haugland HK, Bjerkvig R: Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas. Invasion Metastasis 1997,17(5):270-280.
39. Magkou C, Nakopoulou L, Zoubouli C, Karali K, Theohari I, Bakarakos P, Giannopoulou I: Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res 2008,10(3):R49. 10.1186/bcr2103
40. Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zänker KS, Brandt BH: Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J 2002,16(13):1823-1825.
41. Brandt BH, Roetger A, Dittmar T, Nikolai G, Seeling M, Merschjann A, Nofer JR, Dehmer-Möller G, Junker R, Assmann G, Zaenker KS: c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J 1999,13(14):1939-1949.
42. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004,350(21):2129-2139. 10.1056/NEJMoa040938
43. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004,304(5676):1497-1500. 10.1126/science.1099314
44. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004,101(36):13306-13311. 10.1073/pnas.0405220101